{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=16",
    "query": {
      "intervention": "Placebo once daily",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 5496,
    "total_pages": 550,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T02:17:48.908Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04454567",
      "title": "A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "ABI-H0731",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "NrtI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Assembly Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 2,
      "start_date": "2020-11-11",
      "completion_date": "2021-04-08",
      "has_results": true,
      "last_update_posted_date": "2022-10-20",
      "last_synced_at": "2026-10-15T02:17:48.908Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Pasadena, California • San Diego, California + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04454567"
    },
    {
      "nct_id": "NCT00135421",
      "title": "Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Pexacerfont",
          "type": "DRUG"
        },
        {
          "name": "Escitalopram",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 271,
      "start_date": "2005-11",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2010-03-02",
      "last_synced_at": "2026-10-15T02:17:48.908Z",
      "location_count": 45,
      "location_summary": "Springdale, Arkansas • Orange, California • Upland, California + 39 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Wheat Ridge",
          "state": "Colorado"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00135421"
    },
    {
      "nct_id": "NCT07809919",
      "title": "A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Visceral Leishmaniasis",
        "Chagas Disease"
      ],
      "interventions": [
        {
          "name": "LXE408",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Iohexol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 88,
      "start_date": "2018-12-21",
      "completion_date": "2021-09-27",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-15T02:17:48.908Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07809919"
    },
    {
      "nct_id": "NCT00086736",
      "title": "Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "bicalutamide",
          "type": "DRUG"
        },
        {
          "name": "eflornithine",
          "type": "DRUG"
        },
        {
          "name": "oral eflornithine placebo",
          "type": "DRUG"
        },
        {
          "name": "oral bicalutamide placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 34,
      "start_date": "2001-11",
      "completion_date": "2003-11",
      "has_results": false,
      "last_update_posted_date": "2013-11-19",
      "last_synced_at": "2026-10-15T02:17:48.908Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00086736"
    },
    {
      "nct_id": "NCT00636636",
      "title": "Safety and Efficacy of Gabapentin in Postherpetic Neuralgia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuralgia,Postherpetic"
      ],
      "interventions": [
        {
          "name": "Gabapentin Extended Release tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Depomed",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 452,
      "start_date": "2008-03",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2012-02-22",
      "last_synced_at": "2026-10-15T02:17:48.908Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Lancaster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00636636"
    },
    {
      "nct_id": "NCT01501799",
      "title": "A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "adapalene 0.1% and benzoyl peroxide 2.5% topical gel",
          "type": "DRUG"
        },
        {
          "name": "EPIDUO",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Vehicle Gel)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Mid-Atlantic LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 885,
      "start_date": "2011-07",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2011-12-29",
      "last_synced_at": "2026-10-15T02:17:48.908Z",
      "location_count": 8,
      "location_summary": "Fremont, California • Miami, Florida • Miramar, Florida + 5 more",
      "locations": [
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miramar",
          "state": "Florida"
        },
        {
          "city": "Plainfield",
          "state": "Indiana"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01501799"
    },
    {
      "nct_id": "NCT00528411",
      "title": "A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Ticagrelor Tablets",
          "type": "DRUG"
        },
        {
          "name": "Clopidogrel (over encapsulated) capsule",
          "type": "DRUG"
        },
        {
          "name": "Aspirin Tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 123,
      "start_date": "2007-10",
      "completion_date": "2009-03",
      "has_results": true,
      "last_update_posted_date": "2012-01-13",
      "last_synced_at": "2026-10-15T02:17:48.908Z",
      "location_count": 8,
      "location_summary": "Baton Rouge, Louisiana • Baltimore, Maryland • Towson, Maryland + 5 more",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Towson",
          "state": "Maryland"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00528411"
    },
    {
      "nct_id": "NCT00490971",
      "title": "A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Olanzapine",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone ER",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 768,
      "start_date": "2006-05",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2015-04-15",
      "last_synced_at": "2026-10-15T02:17:48.908Z",
      "location_count": 16,
      "location_summary": "Scottsdale, Arizona • Riverside, California • San Diego, California + 13 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00490971"
    },
    {
      "nct_id": "NCT07635563",
      "title": "DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obstructive Sleep Apnea (OSA)"
      ],
      "interventions": [
        {
          "name": "IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide",
          "type": "DRUG"
        },
        {
          "name": "IHL-42X: 5 mg dronabinol + 125 mg acetazolamide",
          "type": "DRUG"
        },
        {
          "name": "IHL-42X: 7.5 mg dronabinol + 125 mg acetazolamide",
          "type": "DRUG"
        },
        {
          "name": "IHL-42X: 2.5 mg dronabinol + 250 mg acetazolamide",
          "type": "DRUG"
        },
        {
          "name": "IHL-42X: 5 mg dronabinol + 250 mg acetazolamide",
          "type": "DRUG"
        },
        {
          "name": "IHL-42X: 7.5 mg dronabinol + 250 mg acetazolamide",
          "type": "DRUG"
        },
        {
          "name": "IHL-42X: 2.5 mg dronabinol + 375 mg acetazolamide",
          "type": "DRUG"
        },
        {
          "name": "IHL-42X: 5 mg dronabinol + 375 mg acetazolamide",
          "type": "DRUG"
        },
        {
          "name": "IHL-42X: 7.5 mg dronabinol + 375 mg acetazolamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo: Negative control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incannex Healthcare Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 120,
      "start_date": "2026-07-21",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-15T02:17:48.908Z",
      "location_count": 13,
      "location_summary": "Chula Vista, California • Brandon, Florida • Jacksonville, Florida + 9 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07635563"
    },
    {
      "nct_id": "NCT03681093",
      "title": "Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Nasal Polyps"
      ],
      "interventions": [
        {
          "name": "Fevipiprant 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Fevipiprant 450 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2019-03-26",
      "completion_date": "2020-06-10",
      "has_results": true,
      "last_update_posted_date": "2021-10-11",
      "last_synced_at": "2026-10-15T02:17:48.908Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03681093"
    }
  ]
}